CURE’s lung cancer page is an extensive resource of cancer information featuring the latest lung cancer news, expert oncologist insights on the latest cancer treatments, oncology research, advocacy efforts, and medical data on lung cancer.
May 20th 2022
A shared discussion on the importance of enrolling in clinical trials for EGFR exon 20–positive NSCLC and improving access to novel therapy for patients.
A focused conversation on how a patient can maintain and improve quality of life while receiving therapy for non–small cell lung cancer.
May 19th 2022
The Strata PATH trial will use a novel testing strategy to determine if certain patients with solid tumors can benefit from already-approved therapies.
May 13th 2022
Comprehensive discussion on support for patients receiving therapy for NSCLC, ranging from care team members to education materials to support groups.
Looking at available novel therapy for EGFR exon 20 insertion–positive NSCLC, experts consider how patients can play a part in identifying their best treatment option.
May 11th 2022
When it comes to learning about their disease, patients with cancer can have different preferences, from wanting to discuss treatments with their providers or read handouts, while others may not want to know much at all.
May 6th 2022
An expert in the lung cancer and a representative from lung cancer advocacy group talk about the use of amivantamab, a novel therapy approved for treating EGFR exon 20 insertion–positive disease.
A brief discussion on the importance of accessing novel therapy and clinical trials in the setting of EGFR exon 20 insertion–positive NSCLC.
May 2nd 2022
John Wayne coined the term, “the Big C,” for cancer, but I think it’s time that the capital letter C stands for something better.
April 30th 2022
Livia Szeto, B.S.N., RN, OCN, has "unparalleled" patient relationships and research skills, allowing her to provide excellent care.
April 29th 2022
Shared insight on how molecular profiling can impact the management of EGFR exon 20 insertion–positive NSCLC and how patient advocacy groups can help patients to interpret test results.
Experts explain the presence and role of EGFR exon 20 insertion mutations in non–small cell lung cancer and highlight the role of molecular profiling.
April 27th 2022
Imfinzi alone is the standard of care in this patient population, however two combinations may have better outcomes.
April 25th 2022
The drug, known as BDTX-1535, is being investigated in patients with glioblastoma that harbors EGFR alterations and non-small cell lung cancer that harbors EGFR mutations of intrinsic or acquired resistance and disease that has failed standard treatment.
April 18th 2022
Activating mutations in this class of oncogenes, specifically KRAS, have made a big step forward scientifically and clinically just in the last couple of years.
April 16th 2022
Recent advancements surrounding the development of biomarker- targeted therapies have revolutionized the treatment of lung cancer.
April 14th 2022
Patients who are part of an advocacy group may be better equipped to understand biomarker testing during a lung cancer diagnosis and feel more empowered.
Over the past 20 years, advancements in the lung cancer space have led to a drastic paradigm shift in how patients are now treated, ultimately leading to substantial improvements in survival and patient quality of life.
April 13th 2022
The FDA’s recent approval of Opdivo plus chemotherapy may be beneficial for some patients with non-small cell lung cancer, further highlighting the need for multidisciplinary care.
Anti-TIGIT immunotherapy drugs may improve quality of life and survival, while being well tolerated by patients.
April 12th 2022
The KRAS G12C gene mutation in non-small cell lung cancer has been deemed “undruggable,” but recent effective therapies have successfully targeted this mutation, leading to shrinking of tumors and longer survival.
April 11th 2022
As part of its Speaking Out video series, CURE spoke with Sarah Miretti Cassidy, director of external affairs at Cancer Hope Network, about the importance of support following a lung cancer diagnosis.
As part of its Speaking Out video series, CURE spoke with Sarah Miretti Cassidy, director of external affairs at Cancer Hope Network, about the psychosocial effects of a lung cancer diagnosis.
As part of its Speaking Out video series, CURE spoke with Sarah Miretti Cassidy, from Cancer Hope Network, about seeking support for patients who may be nearing end of life, as well as support for family and friends after a loved one has passed.
“It’s important for patients to be educated on (next-generation sequencing), because the more we know about a patient’s cancer, the better we can design a personalized treatment plan,” says an expert.
March 30th 2022
Tiragolumab plus Tecentriq and chemotherapy did not significantly improve progression-free survival and overall survival in patients with extensive-stage small-cell lung cancer.
March 27th 2022
The FDA’s decision follows a recommendation from a panel of experts that suggested the agency not approve sintilimab plus the chemotherapy pemetrexed and platinum-based chemotherapy for patients with non-squamous non-small cell lung cancer.
March 25th 2022
From Pfizer issuing a voluntary recall of three blood pressure drugs due to a high level of a cancer-causing chemical to “Today Show” co-ancho Hoda Kotb discussing her struggles with fertility after receiving a diagnosis of breast cancer, here’s what’s happening in the cancer space this week.
March 21st 2022
March 5th 2022
The FDA’s approval of the Opdivo plus platinum-doublet chemotherapy regimen marks the agency’s first greenlight, according to manufacturer Bristol Myers Squibb, of an immunotherapy-based treatment in the pre-surgical setting for non-small cell lung cancer.
I Was Blindsided by a Cancer I’ve Never Heard Of
The Integration of Complementary Cancer Care May ‘Accelerate’ in Coming Years, Says Patrick Dempsey
Chemotherapy Hair Hacks: From Lint Rollers to Duct Tape
Myelofibrosis Symptom Management Is ‘Incredibly Important’ to Preserve Quality of Life